In some patients who are at higher risk for
bleeding complications, such as the elderly and patients with a history of hemorrhagic events, Does shorter antiplatelet therapy
after stenting
found inferior?
In OPTIMIZE Randomized Trial
That test three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents
The individual components of the combined endpoint did not differ significantly at 1-year follow-up.
All-cause mortality was seen
in 1.9% and 1.7% of the 3- and 12-month therapy groups;
MI rates were 0.8% and 0.6%,
respectively;
Stroke rates were 0.3% and 0.1%;
Major bleeding occurred in 0.2% and
0.4%.
Rates of definite or probable
stent thrombosis at 1 year were 0.3% in the
3-month therapy group and 0.1% in the 12-month group,
There was a trend toward higher risk of
bleeding at 1 year in patients on
12 months of DAPT, seen in 1% compared with
0.4% of those on 3 months of therapy
Landmark analyses also
found no significant differences between groups for these endpoints at 3 months.
